ERBB2 and breast carcinoma: This finding was in accordance with the previous outcomes, in which the HERA trial evaluated 1703 HER2 + early breast cancer patients underwent standard 1-year trastuzumab found a 3-year disease free survival (DFS) of 84.6% in HR + subgroup and 76.4% in HR- subgroup, respectively [38].